| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2015011008 |
| Title |
7-Azaindole Derivatives As Parp Inhibitors. |
| Abstract |
The present invention relates to 7-azaindole derivatives of Formula (I), pharmaceutical compositions containing such derivatives. The invention further relates to said pharmaceutical compositions for use in medicine, and more particularly in the treatment of cancer diseases where an inhibition of PARP is responsive. |
| Applicant(s) |
Sigma-Tau Industrie Farmaceutiche Riunite Spa |
| Representative Drug(s) |
D0JY0L |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013028495 |
| Title |
Dihydropyridophthalazinone Inhibitors of Poly (Adp-Ribose) Polymerase (Parp) for The Treatment of Multiple Myeloma. |
| Abstract |
Provided is a methods of treating multiple myeloma with inhibitors of poly(ADP-ribose)polymerase according to Formula (I):. |
| Applicant(s) |
Biomarin Pharmaceutical Inc |
| Representative Drug(s) |
D0W8EC |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2011130661 |
| Title |
Methods of Using Dihydropyridophthalazinone Inhibitors of Poly (Adp-Ribose)Polymerase (Parp). |
| Abstract |
Provided herein are methods of treating cancer comprising administering a topoisomerase inhibitor, temozolomide, or a platin in combination with a Compound of Formula (I) or Formula (II), where the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. |
| Applicant(s) |
Biomarin Pharmaceutical Inc |
| Representative Drug(s) |
D0W8EC |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2011028580 |
| Title |
Novel forms of A Multicyclic Compound. |
| Abstract |
Alternative forms of Compound I, processes to reproducibly make them and methods of treating patients using them. |
| Applicant(s) |
Cephalon, Inc |
| Representative Drug(s) |
D06VZX |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2008063644 |
| Title |
Method of Radio-Sensitizing Tumors Using A Radio-Sensitizing Agent. |
| Abstract |
The present invention relates to a method of treating cancer using PARP inhibitors as radio-sensitization agents of tumors. Specifically the present invention relates to a method of radio-sensitization of tumors using a compound of Formula (I) or a pharmaceutically acceptable salt form thereof. The present invention also relates to a pharmaceutical compositions of PARP inhibitors for radiosensitizing tumors. |
| Applicant(s) |
Cephalon, Inc |
| Representative Drug(s) |
D06VZX |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2006078711 |
| Title |
Diazabenzo[De]Anthracen-3-One Compounds and Methods for Inhibiting Parp. |
| Abstract |
The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase ('PARP'), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein. |
| Applicant(s) |
Mgi Gp, Inc |
| Representative Drug(s) |
D0JA4K |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2015184145 |
| Title |
Use of Eribulin and Poly (Adp Ribose) Polymerase (Parp) Inhibitors As Combination Therapy for The Treatment of Cancer. |
| Abstract |
The invention features methods for treating cancer in a patient in need thereof by administering eribulin, in combination with one or more PARP inhibitors, and, optionally, a platinum-based antineoplastic drug, and kits therefor. The invention is based in part on the observation that combinations of eribulin mesylate, a PARP inhibitor (e.g., E7449), and, optionally, a platinum-based antineoplastic drug (e.g., carboplatin), show improved (e.g., synergistic) antitumor effects. Therefore, the present invention features methods of preventing and treating cancer (e.g., homologous recombination (HR)-deficient cancer by the use of combinations of eribulin (e.g., eribulin mesylate) and one or more PARP inhibitors (e.g., E7449 or a pharmaceutically acceptable salt thereof (e.g., the tartrate salt), optionally in combination with a platinum-based antineoplastic drug (e.g., carboplatin). |
| Applicant(s) |
Eisai R & D Man Co Ltd |
| Patent ID |
WO2015168544 |
| Title |
Selective Chemotherapy Treatments and Diagnostic Methods Related Thereto. |
| Abstract |
This disclosure relates to methods of identifying subjects that have an increased likelihood of responding to a combination of a poly (ADP) ribose polymerase enzyme inhibitor and a platinum based reagent and optionally other anticancer agents in the course of chemotherapy. In certain embodiments, the disclosure relates to methods of treating cancer comprising administering an effective amount of a poly (ADP) ribose polymerase enzyme inhibitor and a platinum based reagent to the subject in need thereof, wherein the subject is in need thereof because measuring a quantity of RNA isolated from a cancer cell from the subject indicates an increased quantity of the RNA compared to a normal sample, wherein the RNA is associated with one or more of the following genes/pseudogenes GLS, UBEC2, HACL1, MSI2, and LOC100129585. |
| Applicant(s) |
Emory University |
| Patent ID |
WO2015112598 |
| Title |
Therapy Regimen and Methods To Sensitize Cancer Cells Treated with Epigenetic Therapy To Parp Inhibitors In Multiple Cancers. |
| Abstract |
The presently disclosed subject matter provides methods to treat cancer cells using low doses of DNA demethylating agents and poly ADP ribose polymerase (PARP) inhibitors. Methods also are provided for sensitizing a cell to a PARP inhibitor. |
| Applicant(s) |
The Johns Hopkins University |
| Patent ID |
WO2015108986 |
| Title |
Use of Parp Inhibitors To Treat Breast or Ovarian Cancer Patients Showing A Loss of Heterozygosity. |
| Abstract |
In one embodiment, the subject invention relates to a method for treatment of a breast or ovarian cancer patient that includes receiving assay results stating that the patient's tumor exhibits LOH, and administering a PARP inhibitor. In one embodiment, the subject invention comprising: classifying said cancer patient, with the computer system, as being likely to respond to a PARP inhibitor if the data comprises i) one or more deleterious mutations in BRCA1 or BRCA2, or ii) a percentage of the genome having greater than 10 percent LOH as determined by the sum of the lengths of each individual LOH region divided by the total genome length, wherein an LOH region is defined as the presence of homozygosity at multiple contiguous single nucleotides, but excludes whole chromosome or chromosome arm LOH. |
| Applicant(s) |
Clovis Oncology, Inc |
| Patent ID |
WO2015108876 |
| Title |
Combination-Based Treatment Method. |
| Abstract |
The invention rel ates to (among other things ) a method compri sing the steps of (a) administering to a patient a PARP-inhibiting amount of a PARP inhibitor; and (b) administering to the patient a topoisomerase I -inhibiting amount of a long-acting topoisomerase I inhibitor. |
| Applicant(s) |
Nektar Therapeutics |
| Patent ID |
WO2015100257 |
| Title |
Methods and Assays for Determining Reduced Brca1 Pathway Function In A Cancer Cell. |
| Abstract |
Provided herein are methods and assays that can be used to predict whether a subject will or will not respond to a cancer treatment comprising a PARP inhibitor and a DNA damage-inducing chemotherapeutic. |
| Applicant(s) |
The General Hospital Corporation |
| Patent ID |
WO2015040378 |
| Title |
Biomarkers Correlated To Parp Inhibitor Treatment Success In Aml Patients. |
| Abstract |
In one aspect, there is provided a method for predicting responsiveness of a subject to a poly-(ADP-ribose)-polymerase (PARP) inhibitor for treating acute myeloid leukaemia (AML), the method comprising determining whether a chromosomal abnormality selected from t(8;21), t(15;17), t(16;16) and inv(16) is present in a sample obtained from the subject; wherein the presence of the chromosomal abnormality is indicative of responsiveness of the subject to the PARP inhibitor for treating AML. |
| Applicant(s) |
King'S College London |
| Patent ID |
WO2015031536 |
| Title |
Nanoparticle Drug Delivery System and Method of Treating Cancer and Neurotrauma. |
| Abstract |
The invention provides pharmaceutical formulations of inhibitors for poly (ADP-ribose) polymerase (PARP) enzyme. The formulations can be used in the treatment and prevention of cancer as well as the treatment of neurotrauma and neurodegenerative diseases. The PARP inhibitor is delivered in the form of nanoparticles that provide efficient delivery of the inhibitor into cancer cells or other cells and release of the inhibitor within the cells. In treating cancer, the result is killing of tumor cells, whereas in treatment of neurotrauma and neurodegenerative disease, the result is preservation of cell function. |
| Applicant(s) |
Northeastern University |
| Patent ID |
WO2014205105 |
| Title |
Biomarkers of Response To Inhibition of Poly-Adp Ribose Polymerase (Parp) In Cancer. |
| Abstract |
Provided herein are methods of identifying a subject having a poly-ADP ribose polymerase (PARP) inhibitor-sensitive tumor by detecting a genomic gain in chromosome 1q21 and/or chromosome 20q13.3 in a tumor sample from the subject. Also provided are methods of identifying a subject having a PARP inhibitor-sensitive tumor by detecting gene amplification of a CHD1L gene or an RTEL1 gene in a tumor sample from the subject. Further provided are methods of treating a tumor with a genomic gain in chromosome 1q21 and/or chromosome 20q13.3 in a subject by administering an effective dose of a PARP inhibitor. |
| Applicant(s) |
The Regents of the University of California |
| Patent ID |
WO2014138101 |
| Title |
Gene Signature To Predict Homologous Recombination (Hr) Deficient Cancer. |
| Abstract |
Methods for identifying and treating cancers that are homologous recombination (HR)-repair defective. In some aspects, HR defective cancers are treated with a PARP inhibitor therapy. Methods for sensitizing cancers to a PARP inhibitor therapy are also provided. |
| Applicant(s) |
Board of Regents, the University of Texas System |
| Patent ID |
WO2014052550 |
| Title |
Use of Parp Inhibitors To Treat Breast Cancer. |
| Abstract |
This invention provides a method for treating a subject afflicted with breast cancer, comprising concurrently administering to the subject (i) a PARP inhibitor and (ii) an autophagy inhibitor, wherein the amounts of the PARP inhibitor and autophagy inhibitor, when concurrently administered, are therapeutically effective. This invention also provides a related method for inducing the death of a breast cancer cell, as well as a composition comprising (i) a PARP inhibitor, (ii) an autophagy inhibitor, and (iii) a pharmaceutically acceptable carrier. |
| Applicant(s) |
Thomas Jefferson University Lisanti, Michael, P |
| Patent ID |
WO2014008592 |
| Title |
Combinations Comprising Diamidine Compounds and Parp Inhibitors for Use I Treating Cancer. |
| Abstract |
The present application relates to combination comprising a therapeutically effective amount of (1) at least one diamidine compound and (2) at least one PARP inhibitor for inhibiting the proliferation of cancer cells in a patient in need thereof and /or for treating cancer in a patient in need thereof, method and uses thereof. |
| Applicant(s) |
Oncozyme Pharma Inc |
| Patent ID |
WO2013182645 |
| Title |
Methods for Detecting Inactivation of The Homologous Recombination Pathway (Brca1/2) In Human Tumors. |
| Abstract |
The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation. |
| Applicant(s) |
Institut Curie |
| Patent ID |
WO2013133876 |
| Title |
Biomarkers for Prediction of Response To Parp Inhibition In Breast Cancer. |
| Abstract |
Methods and systems for identifying a cancer patient suitable for treatment with a PARP inhibitor. A 6-gene, 7-gene, and 8-gene predictor panels of genes that are predictive of patient resistance or sensitivity to PARP inhibitors such as Olaparib. An exemplary method may comprise: (a) measuring amplification or expression levels of a gene selected from the group consisting of BRCAI, BRCA2, H2AFX, MREIIA, TDG, XRCC5, CHEKI and CHEK2 in a sample from the patient; and (b) comparing the amplification or expression level of the gene from the patient with amplification or expression level of the gene in a normal tissue sample or a reference expression level, wherein an increase of amplification or expression of the gene encoding BRCA2, CHEKI or CHEK2 and/or a decrease of amplification or expression of the gene encoding BRCAI, H2AFX, MREIIA, TDG or XRCC5 indicates the patient will be suitable for treatment with the PARP inhibitor. |
| Applicant(s) |
The Regents of the University of California |
| Patent ID |
WO2013096843 |
| Title |
Methods and Materials for Assessing Loss of Heterozygosity. |
| Abstract |
This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided. |
| Applicant(s) |
Myriad Genetics, Inc |
| Patent ID |
WO2013076295 |
| Title |
Methods for Screening A Brca1 Loss-of-Function In A Subject Suffering From A Cancer. |
| Abstract |
The present invention relates to a method for screening a BRCA1 loss-of-function in a subject comprising the step consisting of determining the level of serine 211 phosphorylated glucocorticoid receptor (GR P-Ser211) expression in a tissue sample obtained from said subject. |
| Applicant(s) |
Insert (Institut National De La Sant et De La Recherche M Icale) |
| Patent ID |
WO2013064895 |
| Title |
Methods for The Detection, Visualization and High Resolution Physical Mapping of Genomic Rearrangements In Breast and Ovarian Cancer Genes and Loci Brca1 and Brca2 Using Genomic Morse Code In Conjunction with Molecular Combing. |
| Abstract |
Methods for detecting genomic rearrangements in BRCA1 and BRCA2 genes at high resolution using Molecular Combing and for determining a predisposition to a disease or disorder associated with these rearrangements including predisposition to ovarian cancer or breast cancer. Primers useful for producing probes for this method and kits for practicing the methods. |
| Applicant(s) |
Genomic Vision |
| Patent ID |
WO2013049581 |
| Title |
Compositions and Methods for The Treatment of Proliferative Diseases. |
| Abstract |
The present invention relates to pharmaceutical compositions that contain PI3K inhibitors (e.g., PBKa-specific inhibitors) and PARP inhibitors. The invention also provides methods for the treatment of proliferative diseases such as cancer (e.g., breast cancer) by administering the composition(s) to a subject. |
| Applicant(s) |
Beth Israel Deaconess Medical Center Inc |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US2015072972 |
| Title |
Phthalazine Derivatives As Parp Inhibitors. |
| Applicant(s) |
Janssen Pharmaceutica Nv |
| Representative Drug(s) |
D0A9HR |
Drug Info
|
IC50 = 15 nM |
Click to Show More |
[1] |
|
2
|
D0AE5G
|
Drug Info
|
IC50 = 17 nM
|
[1] |
| Patent ID |
US2015353526 |
| Title |
Tetrahydrophenanthridinones and Tetrahydrocyclopentaquinolinones As Parp and Tubulin Polymerization Inhibitors. |
| Applicant(s) |
Janssen Pharmaceutica Nv |
| Representative Drug(s) |
D01PSK |
Drug Info
|
IC50 = 58 nM |
Click to Show More |
[1] |
|
2
|
D00JAH
|
Drug Info
|
IC50 = 59 nM
|
[1] |
|
3
|
D0C7HZ
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
US2014243320 |
| Title |
Novel Compound Having Parp Inhibitory Activity. |
| Applicant(s) |
Santen Pharmaceutical Co |
| Representative Drug(s) |
D0IL3B |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US2006276497 |
| Title |
Novel Multicyclic Compounds and The Use Thereof. |
| Applicant(s) |
Teva (Cephalon, Inc.) |
| Representative Drug(s) |
D06VZX |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US2013053365 |
| Title |
Dihydropyridophthalazinone Inhibitors of Poly(Adp-Ribose)Polymerase (Parp). |
| Representative Drug(s) |
D09OSS |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US2015344968 |
| Title |
Methods for Determining Parp Inhibitor and Platinum Resistance In Cancer Therapy. |
| Applicant(s) |
Inst of Fox Chase Cancer Ct |
| Patent ID |
US2015166544 |
| Title |
Piperazinotriazole Compound, Preparation Method Therefor, and Use Thereof In Drug Preparation. |
| Applicant(s) |
Shanghai Institute of Materia Medica |
| Patent ID |
US2015005355 |
| Title |
Combination Therapy with Parp Inhibitors. |
| Applicant(s) |
Abbvie Inc |
| Patent ID |
US2015005354 |
| Title |
Combination Therapy with Parp Inhibitors. |
| Applicant(s) |
Abbvie Inc |
| Patent ID |
US2015005327 |
| Title |
Use of Rnai Inhibiting Parp Activity for The Manufacture of A Medicament for The Treatment of Cancer. |
| Applicant(s) |
Univ. Sheffield |
| Patent ID |
US2013225647 |
| Title |
Combination Therapy with Parp Inhibitors. |
| Applicant(s) |
Abbvie Inc |
| Patent ID |
US2013224312 |
| Title |
Methods and Materials for Assessing Responsiveness To Parp Inhibitors and Platinating Agents. |
| Applicant(s) |
Mayo Foundation |
| Patent ID |
US2013316349 |
| Title |
N-Methylpurine Dna Glycosylase and Polymerase Beta As Biomarkers for Alkylator Chemotherapy Potentiation. |
| China National Intellectual Property Administration (CNIPA) |
| Patent ID |
CN104945406 |
| Title |
Aza-Phenalene-3-Ketone Derivative, Preparation Method Thereof and Application of Aza-Phenalene-3-Ketone Derivative As Parp Inhibitor. |
| Applicant(s) |
Suzhou Kangrun Pharmaceutical Inc |
| Representative Drug(s) |
D0YA6M |
Drug Info
|
N.A. |
[1] |
| Patent ID |
CN104974161 |
| Title |
4H-Pyrazolo[1,5-[Alpha]]Benzimidazole Compound Analogue As Parp Inhibitor. |
| Applicant(s) |
Medshine Discovery Inc |
| Representative Drug(s) |
D06UXE |
Drug Info
|
N.A. |
[1] |
| Taiwan Intellectual Property Office (TIPO) |
| Patent ID |
TW201444842 |
| Title |
Fused Tetra or Penta-Cyclic Dihydrodiazepinocarbazolones As Parp Inhibitors. |
| Applicant(s) |
Beigene Ltd |
| Representative Drug(s) |
D0SS2O |
Drug Info
|
N.A. |
[1] |
| Patent ID |
TW201444839 |
| Title |
Fused Tetra or Penta-Cyclic Pyridophthalazinones As Parp Inhibitors. |
| Applicant(s) |
Beigene Ltd |
| Representative Drug(s) |
D0IL3C |
Drug Info
|
N.A. |
[1] |
